Artificial Intelligence (AI) For De Novo Drug Design Market Outlook Highlighting Expansion Trends Across Industries Through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Artificial Intelligence (AI) For De Novo Drug Design Market In 2026 And 2030?
The artificial intelligence (AI) for de novo drug design market has experienced substantial growth in recent years. It is forecast to increase from $1.9 billion in 2025 to $2.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 33.4%. The expansion observed in prior periods can be linked to high R&D costs in traditional drug discovery, a growing need for faster drug development processes, the adoption of computational chemistry tools, increasing investments within the pharmaceutical sector, and the broadening of academic and research collaborations.
The artificial intelligence (AI) for de novo drug design market size is anticipated to undergo significant growth in the upcoming years, with projections indicating an expansion to $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 33.7%. This forecasted growth is largely driven by the increasing integration of AI-powered lead compound generation, a rise in the utilization of ADMET prediction models, the growing adoption of both cloud and on-premises deployment strategies, the expansion of model development and data annotation services, and enhanced collaboration between pharmaceutical and biotech companies. Prominent trends expected in this period encompass the greater adoption of cloud-based AI platforms, an escalating demand for deep learning-based drug design software, the increasing incorporation of workflow automation in drug discovery, the advancement of molecular property prediction tools, and a heightened emphasis on targeted therapeutic area applications.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Artificial Intelligence (AI) For De Novo Drug Design Market Growth?
The increasing occurrence of complex diseases is anticipated to boost the expansion of the artificial intelligence (AI) for the de novo drug design market moving forward. Complex diseases are defined as health conditions stemming from a combination of genetic, environmental, and lifestyle elements, frequently impacting multiple bodily systems and necessitating sophisticated or prolonged medical care. The rise in complex disease prevalence is attributed to unhealthy lifestyle choices, which elevate the likelihood of chronic ailments such as diabetes, cardiovascular diseases, and specific cancers. Artificial intelligence (AI) for de novo drug design facilitates the discovery of new therapies by examining intricate biological data and forecasting viable drug candidates, thereby addressing the challenges presented by these multifactorial and chronic complex diseases. For example, in February 2024, the World Health Organization, an international organization based in Switzerland, forecast over 35 million new cancer cases by 2050, signifying a 77% increase compared to the estimated 20 million cases reported in 2022. Consequently, the growing prevalence of complex diseases is fueling the development of the artificial intelligence (AI) for de novo drug design market.
Which Segment Categories Are Included In The Artificial Intelligence (AI) For De Novo Drug Design Market Segment Analysis?
The artificial intelligence (AI) for de novo drug design market covered in this report is segmented –
1) By Component: Software, Services
2) By Therapeutic Area: Oncology, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases, Rare Diseases, Metabolic Disorders, Other Therapeutic Areas
3) By Deployment Mode: On-Premises, Cloud-Based
4) By Application: Target Identification, Lead Compound Generation, Molecular Property Prediction, Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction), Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End Users
Subsegments:
1) By Software: Cloud Based Software, On Premise Software, Machine Learning Software, Deep Learning Software, Molecular Modeling Software, Data Analytics Software, Workflow Automation Software
2) By Services: Consulting Services, Integration Services, Maintenance And Support Services, Training And Education Services, Managed Services, Data Annotation Services, Model Development Services
Which Trends Are Contributing To Changes In The Artificial Intelligence (AI) For De Novo Drug Design Market?
Leading companies within the artificial intelligence (AI) for de novo drug design market are prioritizing the development of innovative solutions, such as AI-native drug discovery platforms, to accelerate the creation and refinement of novel small molecules. These AI-native platforms function as integrated systems, utilizing AI models to generate, predict, and select new molecules from the ground up, thereby speeding up drug discovery by identifying promising compounds more quickly and efficiently than traditional trial-and-error approaches. For example, in November 2025, Terray Therapeutics, a US-based biotechnology company, unveiled EMMI (Experimentation Meets Machine Intelligence), an AI-native drug discovery platform specifically engineered for de novo small molecule design. It integrates Terray’s proprietary ultra-miniaturized experimental hardware with an extensively automated laboratory and the Chemistry-Oriented AI Transformer Interface, third generation (COATI3) chemistry foundation model. This integration allows it to generate millions of novel molecules, predict their potency, select the most promising candidates, and iteratively optimize them. The platform’s generative AI employs reinforcement learning to propose synthetically accessible molecules, while predictive AI models swiftly evaluate properties like potency, selectivity, solubility, metabolism, and clearance. Concurrently, the selection AI optimizes which molecules to synthesize, aiming to reduce time and cost by up to threefold compared to industry standards. EMMI is applicable across internal immunology programs and partnerships exploring previously untouched chemical spaces, positioning it as a transformative instrument for de novo drug design.
Who Are The Active Companies Shaping The Artificial Intelligence (AI) For De Novo Drug Design Market?
Major companies operating in the artificial intelligence (AI) for de novo drug design market are Schrödinger Inc., XtalPi Holdings Ltd., Owkin Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd., Generate Biomedicines Inc.
Get The Full Artificial Intelligence (AI) For De Novo Drug Design Market Report:
Where Is The Artificial Intelligence (AI) For De Novo Drug Design Market Primarily Concentrated By Region?
North America was the largest region in the artificial intelligence (AI) for de novo drug design market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) for de novo drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Artificial Intelligence (AI) For De Novo Drug Design Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) For De Novo Drug Design Market 2026, By The Business Research Company
adeno-associated virus (avv) vectors in gene therapy market report 2026
gastric cancer therapy market report 2026
https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report
over the counter (otc) drugs market report 2026
https://www.thebusinessresearchcompany.com/report/over-the-counter-otc-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
